Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prexasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 19/20 | 1.00 |
| ▸ | CHEK2 known ✓ | O96017 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 15/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prexasertib SCHEMBL1975451 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL29371799 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30517001 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL20668254 | 0.99 | CHEK1 (0.98) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL29838776 | 0.99 | CHEK1 (0.98) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL28527965 | 0.99 | CHEK1 (0.98) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL1971742 | 0.98 | CHEK1 (0.96) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL18955240 | 0.98 | CHEK1 (0.96) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL20591301 | 0.95 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL1971000 | 0.95 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4555325-A2 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | Acrivon Therapeutics, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119768688-A | Methods and systems for treating diseases using inhibitors of ATR/CHK1 signaling pathway | 亚克力冯治疗公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4526307-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | Soltego, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-118984707-A | Combination of CHEK1 inhibitors and TOP1 inhibitors for the treatment of colorectal cancer | 基因组研究有限公司 | 2024-11-19 | — | — | CN | disclosed |
| WO-2024015484-A2 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023225097-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | CHEK1, CHEK2, BUB1 | CHEK1 1/4885CHEK2 2/4885KCNH2 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.